Mabvax Therapeutics (MBVX) Inactive 10-Q2017 Q2 Quarterly report

Filed: 14 Aug 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: AACR, accuracy, adding, allocated, alternative, Arizona, arm, arrangement, ASCO, assist, assisting, attending, blocker, Bone, broadly, CEO, cold, College, colon, conserve, Cornell, cut, deferral, Denver, directly, discontinued, divestiture, dosimetry, earnest, Eileen, employment, entity, Error, exact, exceed, facilitating, feasibility, fit, found, gemcitabine, goal, goodwill, growth, highest, histopathology, Honor, hundred, immunopet, inaccordance, inbound, injection, insight, interfere, inventory, Joint, larger, lesion, literature, lung, margin, marked, Marketplace, maximize, maximizing, media, Medicine, move, Nuclear, objective, personnel, physician, platform, podium, population, portfolio, poster, prioritization, produced, Professor, profile, promised, promising, proven, quickly, radiotracer, reader, regressed, regression, repriced, resolved, revised, Rubenstein, safe, scheduling, Scottsdale, Secondary, selected, shareholder, SNMMI, social, suppression, SUV, talk, team, threshold, timeline, traditional, twelve, typically, unlock, uptake, visualized, voluntary, volunteered, Weill, whichever, York

Removed: cancel, Certification, IND, initiate, leased, receivable, standalone

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

MBVX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of MabVax Therapeutics Holdings, Inc., does hereby certify, to such officer’s knowledge, that:

The Quarterly Report on Form 10-Q of MabVax Therapeutics Holdings, Inc. for the three and six months ended June 30, 2017, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of MabVax Therapeutics Holdings, Inc.


Date: August 14, 2017	By:	/s/ J. David Hansen
		J. David Hansen
		Chief Executive Officer (Principal Executive Officer)

Date: August 14, 2017	By:	/s/ Gregory P. Hanson
		Gregory P. Hanson
		Chief Financial Officer (Principal Financial and Accounting Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.